Saatja: "Noodla-Pärna, Liis" <
[email protected]>
Saaja: "Ravimiamet" <
[email protected]>
Teema: Toimeaine camizestrant eesti keeles
Kuupäev: 2025-01-27 08:59
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu
saatja korral palume linke ja faile mitte avada.
Tere!
Igaks juhuks konsulteeriks Ravimametiga üle, et kas toimeaine
„camizestrant“ tõlgime eesti keelde kui „kamisestrant“?
Suur aitäh ette!
Tervitades
Liis Noodla-Pärna
Regulatory Affairs Manager, Nominated Signatory
__________________________________________________________________________
___________________
AstraZeneca
CEE-BA MC| Medical & Regulatory | Baltics
Valukoja 8, 11415 Tallinn, Estonia
T: +372 654 9600 M: +372 53 889 588
<mailto:
[email protected]>
[email protected]
Please consider the environment before printing this e-mail
This e-mail is intended solely for the use of the addressee. In case the
addressee is an AstraZeneca employee only it is not meant for distribution
or disclosure outside AstraZeneca.The information in this e-mail may be
personal or confidential and may be subject to attorney-client privilege
or other confidentiality protections. Any views or opinions presented do
not necessarily represent those of AstraZeneca. Should you receive this
message by mistake, please notify the sender immediately and delete this
e-mail from your system without opening the attachment.
Please consider the environment before printing this e-mail.